Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 13/20 | 0.67 |
| ▸ | BCL2 | P10415 | 11/20 | 0.65 |
| ▸ | BAD | Q92934 | 4/20 | 0.63 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.62 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | ASPH | Q12797 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | MDM4 | O15151 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | BID | P55957 | 1/20 | 0.59 |
| ▸ | BAX | Q07812 | 1/20 | 0.59 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.59 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.59 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463310 | 0.95 | BCL2 (0.64) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19424240 | 0.93 | BCL2 (0.72) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19425083 | 0.93 | BCL2 (0.73) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19424355 | 0.92 | BCL2 (0.74) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19424302 | 0.92 | BCL2 (0.61) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL12781273 | 0.90 | BCL2L1 (0.61) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19425078 | 0.89 | BCL2L1 (0.68) | BCL2L1BCL2BAD | |
| SCHEMBL12574586 | 0.88 | BCL2 (0.63) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL15417701 | 0.88 | BCL2 (0.63) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19424431 | 0.88 | BCL2 (0.66) | BCL2L1BCL2BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8624027-B2 | Combination therapy for treating cancer and diagnostic assays for use therein | ABBVIE INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20100227838-A1 | Combination Therapy for Treating Cancer and Diagnostic Assays for Use Therein | ABBOTT LABORATORIES (US) | 2010-09-09 | — | — | US | disclosed |
| US-7709467-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080287419-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| US-7390799-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | ABBVIE INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287419-A1 | APOPTOSIS PROMOTERS | BAX, API5, BCL2 | BCL2L1 12/4885BCL2 3/4885BAD 6/4885 |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | BAX, BCL2L1, BCL2A1 | BCL2L1 2/4885BCL2 4/4885BAD 9/4885 |
| US-20100227838-A1 | Combination Therapy for Treating Cancer and Diagnostic Assays for Use Therein | FOLH1, TP53, NTPCR | BCL2L1 1781/4885BCL2 2228/4885BAD 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.